Stockscreener 앱 받기
27.74
3.61%
-1.04
전일 마감가:
$28.78
열려 있는:
$28.66
하루 거래량:
1.57M
Relative Volume:
0.92
시가총액:
$3.47B
수익:
$415.62M
순이익/손실:
$-2.38M
주가수익비율:
-976.76
EPS:
-0.0284
순현금흐름:
$16.92M
1주 성능:
+7.48%
1개월 성능:
+19.41%
6개월 성능:
-1.70%
1년 성능:
+81.66%
1일 변동 폭
$26.96
$28.98
1주일 범위
$25.25
$29.84
52주 변동 폭
$13.70
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
27.74 | 3.47B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Understanding Momentum Shifts in (ARQT) - Stock Traders Daily
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st
BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology Digest
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus
FDA accepts Arcutis application for infant eczema treatment - Investing.com
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants - Moomoo
FDA accepts Arcutis application for infant eczema treatment By Investing.com - Investing.com India
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - The Manila Times
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Arcutis Biotherapeutics (ARQT) Rises 4.6% as Biotech Sector Momentum Drives Shares HigherResistance Breakout Stocks - dars.gov.et
Price to sales forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
3 Healthcare Stocks Built For Higher Rates And Steady Demand - Sahm
Arcutis Biotherapeutics (ARQT) Edges Lower, Tests Key Support Levels Amid ConsolidationEquity Put Call - dars.gov.et
Comparative Analysis of Arcutis and Vertex Biotherapeutics - Intellectia AI
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? - The Motley Fool
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis lures 9 new hires with 61,000 stock awards - Stock Titan
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis launches virtual dermatology platform for skin conditions By Investing.com - Investing.com India
Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast - The Dermatology Digest
Avoiding Lag: Real-Time Signals in (ARQT) Movement - Stock Traders Daily
Arcutis launches virtual dermatology platform for skin conditions - Investing.com
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - The Manila Times
Arcutis’ new virtual dermatology platform targets care gaps for 45M Americans - Stock Titan
FDA approves Zoryve cream for plaque psoriasis in children age 2+ - Investing.com India
FDA approves Zoryve cream for plaque psoriasis in children age 2+ By Investing.com - Investing.com India
Arcutis Biotherapeutics stock edges lower with bullish trend intact after once-daily cream approval - Traders Union
Arcutis Biotherapeutics (ARQT) Secures FDA Approval for ZORYVE C - GuruFocus
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 - The Manila Times
Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2 - Quiver Quantitative
FDA broadens Arcutis’ ZORYVE to children as young as 2 - Stock Titan
Arcutis Biotherapeutics (ARQT) Edges Higher as Bullish Momentum BuildsBreakout Trade - dars.gov.et
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo
Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT) - TradingView
ARQT Forecast — Price Target — Prediction for 2027 - TradingView
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Globe and Mail
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price - ChartMill
Discipline and Rules-Based Execution in ARQT Response - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Holds Steady Near Support as Investors Eye ResistanceBearish Pattern Stocks - dars.gov.et
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Arcutis director Sue-Jean Lin sells $120,586 in company shares By Investing.com - Investing.com Australia
Insider Sell Alert: Sue-jean Lin Sells Shares of Arcutis Biother - GuruFocus
Arcutis director Sue-Jean Lin sells $120,586 in company shares - Investing.com
Arcutis Biotherapeutics Inc (ARQT) Institutional Confidence - TradingKey
Arcutis (ARQT) director Sue-Jean Lin executes planned share sale - Stock Titan
Arcutis (ARQT) director trades shares under Rule 10b5-1 stock plan - Stock Titan
Arcutis Biotherapeutics Inc (ARQT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):